CClinicalTrials.gg
RecruitingNCT06074315Updated Dec 8, 2023

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

An interventional study of Nail Genesis DLSO Product and Nail Genesis DLSO Product (vehicle only) in Distal Lateral Subungual Onychomycosis and Onychomycosis, sponsored by Nail Genesis LLC. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by Nail Genesis LLC · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle.

Subject eligibility will be determined during a Screening assessment. Subjects will complete a 4week washout period after discontinuation of a topical product or a 12-month washout period after discontinuation of an oral product or light-based therapy prior to randomization. Eligible subjects will be randomized in a 2:1 ratio to receive Nail Genesis DLSO Product or vehicle, respectively. During the 52-week trial, study medication will be administered once daily to the target toenail for 48 weeks.

A subject will be considered to have completed the study when he or she has completed the study assessments at Week 52. The 52-week visit is for follow-up safety assessments.

02

Conditions studied

  • Distal Lateral Subungual Onychomycosis
  • Onychomycosis

Browse trials for

03

In context

Onychomycosis

147 studies on the registry are indexed under Onychomycosis; 13 are open to participants now.

This study's planned enrollment of 338 is above the median of 56 across 134 interventional studies indexed under Onychomycosis.

Browse Onychomycosis studies →

Lead sponsor

This is the only study on the registry with Nail Genesis LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject is male or female, and 18 to 65 years of age, inclusive.
  • Subject has nail fungal infection of at least one great toenail (per visual assessment, positive KOH preparation, and positive dermatophyte culture).
  • Subject has target toenail showing 20-50% involvement without matrix (lunula) involvement.
  • Subject has 3 mm of unaffected nail (from proximal nail fold) on target toenail.
  • Subject has target toenail thickness of 3 mm or less.
  • Subject must be physically able to reach toes to clean, trim, and apply product to the target toenail.
  • Subject is willing and available to return for study follow up.
  • Subject or legal representative is able to understand and provide signed consent for participating in the study.
  • Female subject of childbearing potential has negative urine pregnancy test.
  • Females must be post-menopausal or must agree to use approved contraceptives (actions, de- vices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (abstinence is NOT an accepted form of contraception).

Exclusion criteria

Exclusion Criteria:

  • Subject has known hypersensitivity or allergy to the product materials.
  • Subject has negative KOH preparation or dermatophyte culture.
  • Subject has dermatophytoma on target toenail.
  • Subject is enrolled in another investigational drug, device, or product protocol that would interfere with this study.
  • Subject is using other topical or pharmaceutical treatments for any nail conditions; a wash-out period of at least four weeks after discontinuation of a topical product or 12 months after discontinuation of an oral product or light-based therapy for treatment of nail fungus is required.
  • Subject has history of immunosuppression and/or clinical signs indicative of possible immunosuppression.
  • Subject with possible chronic disease, including: diabetes, psoriasis, immune deficiency (HIV), severe foot injury, chronic vascular disease, or in which delayed treatment (approved treatment) of DLSO for one year could present a significant health concern.
  • Subject has presence of toenail infection other than dermatophytes on target toenail.
  • Subject has any disease/condition that might cause toenail abnormalities or interfere with evaluation.
  • Subject has had previous toenail surgery on target toenail.
  • Subject is a pregnant or nursing female.
  • Subject is an Investigator, Nail Genesis' personnel, or Nail Genesis' Scientific Advisory Board (SAB) members, or their immediate family.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
338 participants (estimated)

Study arms

  • Experimental
    Nail Genesis DLSO Product

    Nail Genesis DLSO Product, poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.

    Device: Nail Genesis DLSO Product

  • Placebo comparator
    Vehicle

    poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.

    Device: Nail Genesis DLSO Product (vehicle only)

Interventions

  • DeviceNail Genesis DLSO Product

    Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).

  • DeviceNail Genesis DLSO Product (vehicle only)

    The Nail Genesis DLSO product poly-urethane vehicle

06

What researchers measure

Primary outcomes

  1. Effectiveness - Complete Cure

    Proportion of subjects with Complete Cure (0% involvement of the target toenail in addition to Mycologic Cure (defined as both negative KOH stain and negative dermatophyte culture).

    Time frame: Week 48

  2. Safety - Adverse Events

    Proportion of subjects with treatment-emergent AEs of Nail Genesis DLSO Product compared with vehicle control)

    Time frame: Week 48

Secondary outcomes

  1. Almost complete cure

    Proportion of subjects achieving almost Complete Cure (\< 10% clinical involvement of the target toenail) in addition to Mycologic Cure.

    Time frame: Week 48

  2. Mycological Cure

    Proportion of subjects achieving Mycologic Cure of the target toenail at Week 48

    Time frame: Week 48

07

Study locations

9 of 10 sites recruiting
  • Clinical Trials Institute of Northwest Arkansas
    Fayetteville, Arkansas 72703, United States
    Recruiting
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
    Recruiting
  • Northern California Research
    Sacramento, California 95821, United States
    • Laurie Johnson · Contact · ljohnson@norcare.net · 916-484-0500
    • Douglas Young, MD · Principal investigator
    Recruiting
  • Metro Clinical Trials
    San Bernardino, California 92404, United States
    Recruiting
  • Doctors Research Network
    South Miami, Florida 33143, United States
    • Patria Divison · Contact · pdivison@drnmiami.com · 305-665-3017
    • Maria Surprenant, MD · Principal investigator
    Recruiting
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
    Not yet recruiting
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
    Recruiting
  • DermResearch
    Austin, Texas 78759, United States
    Recruiting
  • West Houston Clinical Research Service
    Houston, Texas 77055, United States
    • Braulio Suarez, MD · Contact · bsuarez@whcrs.com · 281-738-2642
    • Oscar De Valle, MD · Principal investigator
    Recruiting
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06074315
Lead sponsor
Nail Genesis LLC
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Oct 1, 2023
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Dec 8, 2023

Study contacts

Brittany Ishmael
Contact
brittany.ishmael@brightps.com
719 321 0876

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion